Two flops in two weeks for Marinus Pharmaceuticals' ganaxolone
Days after Marinus Pharmaceutical’s ganaxolone failed on an epilepsy study, the same drug failed a Fragile X syndrome trial, further bruising the biotech’s already badly damaged market value.
Rather incredibly, the biotech ($MRNS) claims it didn’t expect to hit the primary endpoint: overall improvement across the Fragile X syndrome. Instead the biotech hailed data on ganaxolone’s effectiveness in treating anxiety for patients and intends to use that to find some path forward for the GABAA modulator.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
